Business Context and Reporting Period
This Form 8-K is filed by Cortexyme, Inc. (CRTX) on February 2, 2022, reporting events occurring on January 28, 2022. The filing addresses significant operational changes, executive departures, and pipeline updates following a clinical hold on the company's lead asset, atuzaginstat (COR388).
Key Financial Metrics
- Liquidity: Preliminary, unaudited cash, cash equivalents, and investments totaled $126.7 million as of December 31, 2021.
- Cost Reduction Program: The Board approved a plan to reduce headcount by approximately 53%, with a majority of reductions occurring by March 2022.
- Projected Savings: The company expects annualized operating expense savings of approximately $8.3 million for the year ending December 31, 2022 (excluding share-based compensation).
- One-Time Costs: Estimated expenses related to the reduction in force range from $1.9 million to $2.1 million, substantially all cash expenditures through Q1 2023.
- Severance Payments: Cash severance of $604,000 for the departing CEO and $326,250 for the departing Chief Scientific Officer.
Note: The filing does not provide audited revenue, profit, or margin data for the period. The company is a pre-revenue biopharmaceutical entity.
Material Changes
- Executive Departures: Casey C. Lynch (President, CEO, Chair) and Stephen S. Dominy, M.D. (CSO, Director) departed effective January 28, 2022.
- Leadership Transition: Christopher Lowe (COO/CFO) was appointed Interim CEO and added to the Board. David A. Lamond was appointed Chairperson of the Board.
- Operational Restructuring: A 53% workforce reduction was initiated to rationalize operations following the clinical hold on COR388.
Guidance, Outlook, and Risks
Pipeline Milestones for 2022:
- COR588 (Alzheimer's): Phase 1 SAD/MAD trial results expected in Q2 2022; plans to advance to Phase 2 pending FDA interaction.
- Atuzaginstat (COR388): Potential new indication for prevention of oral/head and neck squamous cell carcinoma (O/HNSCC); plans to submit an IND to the FDA in Q1 2022.
- Periodontal Disease: Intent to develop an oral formulation of gingipain inhibitors.
- COR803 (Coronavirus): Progressing IND-enabling preclinical studies for a 3CLpro inhibitor.
Risks and Contingencies:
- The preliminary cash position is unaudited and subject to change.
- Forward-looking statements regarding clinical trial timelines, FDA submissions, and cost savings are subject to substantial uncertainty.
- The clinical hold on COR388 necessitated the cost-cutting measures and leadership changes.
Investor Verification Checklist
- Verify the final audited cash position for the year ended December 31, 2021, in the upcoming Form 10-K.
- Monitor the status of the FDA clinical hold on atuzaginstat (COR388) and the outcome of the pre-IND meeting for the O/HNSCC indication.
- Track the execution of the 53% workforce reduction and the realization of the projected $8.3 million in annualized savings.
- Confirm the timeline for the Phase 1 results of COR588 in Q2 2022.
- Review the full text of the separation agreements for the departing executives filed as exhibits to the 10-K.